Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

Elevated ribosome biogenesis in oncogene‐driven cancers is commonly targeted by DNA‐damaging cytotoxic drugs. Our previous first‐in‐human trial of CX‐5461, a novel, less genotoxic agent that specifically inhibits ribosome biogenesis via suppression of RNA polymerase I (Pol I) transcription, revealed...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:EMBO J
Prif Awduron: Kusnadi, Eric P, Trigos, Anna S, Cullinane, Carleen, Goode, David L, Larsson, Ola, Devlin, Jennifer R, Chan, Keefe T, De Souza, David P, McConville, Malcolm J, McArthur, Grant A, Thomas, George, Sanij, Elaine, Poortinga, Gretchen, Hannan, Ross D, Hannan, Katherine M, Kang, Jian, Pearson, Richard B
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604608/
https://ncbi.nlm.nih.gov/pubmed/32945574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embj.2020105111
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg